I nflammation-related cardiovascular disturbance is regarded as a pivotal event in the development of atherosclerosis. 1 C-reactive protein (CRP), a biomarker of inflammation and cardiovascular deterioration, is becoming an emerging risk factor for cardiovascular disease. The landmark Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) study recently showed that statin therapy significantly reduced the CRP levels, along with the incidence of major cardiovascular events, in apparently healthy individuals with elevated CRP (≥2 µg/mL).
2,3Despite the lack of direct evidence for a causal link of CRP, accumulating findings suggest that CRP is actively involved in promoting adverse cardiovascular outcomes because of its proatherogenic effects on vascular cells. 4 In cell culture models, CRP, at relatively high pharmacological concentrations (25-100 µg/mL), has been shown to elevate reactive oxygen species generation from vascular cells 5,6 and impair nitric oxide (NO) synthase (NOS) activity and NO production, 7,8 as well as prostacyclin (PGI 2 ) release, 5 from endothelial cells. Extending the studies from a homogeneous cell type in culture, we recently demonstrated in intact coronary arterioles that CRP, at a clinically relevant concentration (7 µg/mL), impairs endothelium-dependent NO-mediated and PGI 2 -mediated dilations by reducing NO bioavailability 9 and inhibiting PGI 2 synthase activation, respectively.10 The detrimental effect of CRP on vasodilator function depended on endothelial production of reduced form of nicotinamide dinucleotide phosphate (NAD[P]H) oxidase-derived superoxide